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Abstract
Purpose of Review Diagnosis during early stages of invasive
aspergillosis (IA) and targeted antifungal treatment has the
potential to improve survival significantly. Despite advances
in the diagnostic arsenal, invasive mold infections remain dif-
ficult to diagnose—especially at early stages before typical
radiological signs develop. Varying availability and time-to-
results are important limitations of current approved bio-
markers and molecular assays for diagnosis of IA. Here, we
will give an update on the Aspergillus-specific lateral-flow
device (LFD) test. We further review promising findings on
feasibility of point-of-care (POC) detection of urinary excret-
ed fungal galactomannan-like antigens.
Recent Findings POC LFD assays for detection of Aspergillus
antigens are currently in development. The Aspergillus-specific
LFD test, which is based on the JF5 antibody (Ab), detects an
extracellular glycoprotein antigen secreted during active growth
of Aspergillus spp. The test has shown promising results in
various studies. In addition, a monoclonal Ab476-based LFD
for POC detection of urinary excreted fungal galactomannan-
like antigens has been developed but needs further validation.
Summary Important advances have been made in the devel-
opment of LFD assays for IA. Most promising is the
Aspergillus-specific LFD test; commercial availability is still
pending, however. The search for reliable POC tests for other
molds, including mucorales, continues.
Keywords Aspergillus lateral flowdevice test . Point of care .
Galactomannan-like antigens .MAb476 . JF5 .
Bronchoalveolar lavage . Urine . Serum .Monoclonal
antibody . Invasive aspergillosis
Introduction
Invasive aspergillosis (IA) is associated with high mortality
rates [1–5]. Early and reliable diagnosis and rapid initiation of
appropriate antifungal therapy has been shown to improve
survival significantly [6, 7]. Culture-based approaches are im-
portant for detection of fungal species and resistance testing;
however, they are limited by low sensitivities—in particular
during early phases of infection—and long turnaround time
[8•]. Significant advances to the field were brought by the
introduction of non-cultural diagnostic tests for IA in blood
and bronchoalveolar lavage fluid (BALF), including
galactomannan antigen (GM) testing [9•, 10 –13], PCR
[14••, 15, 16••, 17], and beta-D-glucan (BDG) testing
[18–24] in patients at risk [25•, 26, 27, 28•, 29]. In line with
the introduction of non-cultural diagnostic tests, the rate of
fungal infections diagnosed pre-mortem (versus post-
mortem) was shown to increase from 16 to 51% in a large
autopsy study [30].
Despite these significant advancements, the availability of
these non-cultural diagnostic tests and time-to-results often
varies with the size, specialization, and resources of the med-
ical institution. “Pregnancy test-like” point-of-care lateral flow
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assays for detection of Aspergillus antigens are currently in
development and may overcome these limitations.
Aspergillus-Specific Lateral Flow Device Test
The point-of-care Aspergillus-specific lateral-flow device test
(LFD) uses a mouse monoclonal antibody, JF5, which binds
to an extracellular glycoprotein antigen secreted by
Aspergillus spp. only during active growth [31]. The LFD
can be used for testing of serum and BALF samples and
shows cross-reaction with Penicillium spp. only [31]. While
serum samples require heating, centrifugation, and addition of
a buffer solution before testing, BALF samples can be tested
without any pre-treatment [32]. After 15 min of incubation
time, results are read by the naked eye and are interpreted
depending on the intensity of the test line as negative (−) or
weak (+) to strong (+++) positive and have been shown to be
reproducible between laboratories and studies [33, 34].
To date, two studies evaluated the diagnostic performance
of the LFD in serum samples from adult patients with hema-
tological malignancies [14, 35•], reporting sensitivities of 40
and 82% and specificities 87 and 80% for probable/proven
invasive aspergillosis (IA) according to modified EORTC/
MSG criteria [36], respectively. A meta-analysis, which in-
cluded also data from the LFD development study [31] (i.e.,
in addition to the two studies mentioned above), reported a
pooled sensitivity of 68% (95% confidence interval (CI), 52–
81%), specificity of 87% (95% CI, 80–92%), and diagnostic
odds ratio (DOR) of 11.90 (95% CI, 3.54–39.96) for differen-
tiating proven/probable versus no IA cases in serum samples
[37•]. Another very recently published study ignored the rec-
ommendations of the manufacturer by using the LFD in serum
samples without pretreatment and found poor performance
confirming that pretreatment of serum samples is a necessary
step and that recommendations of the manufacturer should be
followed [38]. Overall, the requirement for pretreatment has
been a major limitation of serum LFD testing, as has been the
inconsistency of reported results. Further studies, including
multicenter studies, are needed to determine whether LFD
serum testing can be recommended for clinical routine.
In contrast to serum testing, BALF LFD testing has
been evaluated in a number of studies including multi-
center studies and in different patient populations.
Results from the first four-part, retrospective-part, pro-
spective studies (including two multicenter studies)
which evaluated the LFD in mostly patients with under-
lying respiratory diseases [39••] and solid organ trans-
plant recipients [28, 40••, 41] but also a smaller propor-
tion of patients with underlying hematological malignan-
cies [28, 41], were summarized in the meta-analysis
reporting a pooled sensitivity of 86% (95% CI, 76–
93%), specificity of 93% (95% CI, 89–96%), and DOR
of 65.94 (95% CI, 27.21–159.81) for IA when using
BALF samples [37].
Since then, BALF LFD testing has been evaluated in mul-
ticenter studies in intensive care unit patients [42••] and pa-
tients with underlying hematological malignancies [43], as
well as a number of single-center studies [16••, 44–47]. The
up-to-date performance of the LFD in BALF samples for dif-
ferent patient groups as well as the overall performance per
sample are depicted in Table 1. Published data indicates that to
date, 792 BALF samples have been tested at 6 different med-
ical universities, including 113 samples from patients with
probable/proven IA and 552 samples from patients with no
evidence of IA, resulting in an overall sensitivity of 73% and
specificity of 90% for probable/proven IAversus no evidence
for IA. While the overall positive predictive value (PPV) was
61% and the negative predictive value (NPV) 94% in samples
tested to date, both PPV and NPV will depend on the preva-
lence of IA in tested populations as displayed in Fig. 1. For
example, in a patient cohort with an IA prevalence of 1%, the
PPVwill be 7.6%, while the NPVwill be 99.7%; the PPVwill
go up and the NPV down with increase of IA prevalence (e.g.,
5% IA prevalence: PPV 28%, NPV 98.4%; 10% IA preva-
lence: PPV 45%, NPV 96.8%; 20% IA prevalence: PPV 65%,
NPV 93%; always assuming 73% sensitivity and 90%
specificity).
Table 1 Per BALF sample
performance of the BALF
Aspergillus LFD for probable/
proven invasive pulmonary
aspergillosis versus no evidence
for invasive pulmonary
aspergillosis in different patient
cohorts (percentage and absolute
numbers)a
Patient group Sensitivity Specificity PPV NPV
Overallb 73% (83/113) 90% (498/552) 61% (83/137) 94% (498/528)
Solid organ transplantation 94% (15/16) 92% (89/97) 65% (15/23) 99% (89/90)
Intensive care unit 79% (26/33) 85% (176/206) 46% (26/56) 96% (176/183)
Respiratory diseases 78% (25/32) 91% (196/215) 57% (25/44) 97% (196/203)
Hematological malignancies 67% (36/54) 91% (126/139) 73% (36/49) 88% (126/144)
PPV positive predictive value, NPV negative predictive value
a Data derived from published studies [8•, 16••, 28•, 32, 33, 39–47, 48••]:
b Overall summarizes unique samples and is lower than the sum of subgroup samples, as some samples were
classified into more than one subgroup
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Table 2 summarizes LFD results in 127 samples from pa-
tients with possible IPA according to modified EORTC/MSG
criteria [36, 49], as well as patient subgroups. The LFD resulted
positive in 39% of possible IA samples versus 10% of samples
from patients with no evidence of IA. When considering that
diagnostic test performance calculations in the field of IA are
limited by the insensitivity of all current diagnostics (including
GM), these results may indicate that the LFD has additional
discriminatory power in those with possible IPA, i.e., positive
LFD results may provide evidence that some of those with
possible IPA do in fact have (probable) IPA and a false negative
GM test result. If true, positive BALF LFD test results should
be considered as a future mycological factor (in addition to
GM, culture, and PCR) for updated EORTC/MSG criteria.
When comparing different patient populations (Table 1),
LFD sensitivity was lower in patients with underlying hema-
tologic malignancies (67% sensitivity) compared to other pa-
tient groups. The most likely reason for lower sensitivity in
patients with hematological malignancies is the frequent use
of antifungal prophylaxis/empirical antifungal therapy that is
beneficiary for survival in this patient population [50–56].
Similar to other fungal diagnostics, sensitivity of the LFD
was reduced in the presence of antifungal prophylaxis/
treatment (sensitivity 56% in those with mold active antifun-
gals versus 86% in those without; p = 0.0097 Fisher’s exact
test; Table 3) [8•]. The solution is combining the LFD with
other biomarkers such as GM in BALF and/or serum, PCR, or
novel biomarkers such as triacetylfusarinine C (TAFC) [14••,
Fig. 1 Overall positive and
negative predictive values of the
bronchoalveolar lavage fluid
Aspergillus-specific lateral flow
device test in cohorts with
prevalence rates of invasive
aspergillosis between 1 and 30%.
The overall sensitivity of 73% and
specificity of 90% were used for
the calculation
Table 2 Performance of the
BALFAspergillus LFD in cases
of possible invasive pulmonary
aspergillosis (per BALF sample)
in different patient cohorts.a
Patient group Positive LFD Result
Percentage (absolute numbers)
Negative LFD Result
Percentage (absolute numbers)
Overallb 39% (50/127) 61% (77/127)
Solid organ transplantation 33% (4/12) 66% (8/12)
Intensive care unit 37% (14/38) 63% (24/38)
Respiratory diseases 65% (20/31) 35% (11/31)
Hematological malignancies 32% (26/81) 68% (55/81)
a Data derived from published studies [16••, 28•, 39•, 40, 41, 42••, 43••, 46, 47]
b Overall summarizes unique samples and is lower than the sum of subgroup samples, as some samples were
classified into more than one subgroup
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16••, 28, 43••, 45, 48••], which has been shown to increase
sensitivity substantially and helps to overcome this limitation.
After issues emerged with the previousmanufacturing part-
ner, redevelopment workwas undertaken byOLMdiagnostics
after it was given full control to develop and manufacture the
assay on top of its original role as sales and marketing partner.
Development work is well underway and OLM are expecting
to start production over the coming months and launch the
LFD by the end of 2017.
Lateral Flow Device for Galactomannan-Like Antigens
in Urine
Antigen testing of urine samples may provide important
advantages, including non-invasive and easy sample col-
lection that allows for more frequent examination of large
volumes, which may increase test sensitivity and also has
great potential for home testing [57, 58••]. Recent studies
have indicated that GM testing may be promising in urine
samples [57, 59, 60], while results for urine BDG testing
were less convincing [61]. Fisher and colleagues reported
lower specificity of GM testing of urine specimens com-
pared to serum (80% versus 95%) in pediatric hematolog-
ic malignancy patients; however, urine GM testing suc-
cessfully identified the only case of probable IA [60].
These preliminary results were confirmed in a study con-
ducted in adult hematologic malignancy patients by
Duettmann and colleagues [62]. In that study, 242 same-
day serum and urine samples were included from 75 adult
patients prospectively and consecutively. Out of these 75,
10 patients met criteria for probable IA; 3 additional pa-
tients were tested positive for serum GM levels. Urine
samples were not pretreated before GM testing, and urine
GM levels showed a significant positive correlation with
serum GM levels. Sensitivity of urine GM testing was
limited and only improved when using an extremely low
GM cut-off of 0.1 optical density index (ODI). With that
cut-off, urine GM testing exhibited 71% sensitivity and
88% specificity for probable IA. Recently, Reischies and
colleagues showed in another prospective study in adult
patients with hematological malignancies that test perfor-
mance in urine samples can be improved by calculation of
the urine GM/creatinine ratio, which takes urine dilution
into account and may be a promising diagnostic tool for
patients with hematological malignancies [57]. With a
threshold of 0.26 ((urine GM [ODI] × 100)/(urine creati-
nine [mg/dL])), the positive predictive value of 13% was
low, but the negative predictive value of >98% would
qualify this diagnostic method for ruling out IA in high-
risk patients [57].
Given this promising results, development of a point of
care (POC) test for diagnosis of IA in urine samples has the
potential of impacting patient care and associated costs signif-
icantly, as such a test may allow for home testing for IA.
Dufresne and others recently reported that their new monoclo-
nal antibody MAb476 was capable to detect GM-like antigen
(Ag) in urine samples [58••]. Using in vitro and animal exper-
iments, Dufresne and others [58••] investigated renal clear-
ance of serum GM-like Ag in mouse models infected with
A. fumigatus and generated MAb476. MAb476-based sand-
wich-ELISAs (sELISA) reliably detected GM-like Ag in
bronchoalveolar lavage fluid, serum, and lung tissue of neu-
tropenic mice and urine samples from guinea pigs after infec-
tion with air-borne IA [58••]. Experiments showed a specific
affinity of MAb476 to Aspergillus spp. (excluding A. terreus)
as well as Fusarium spp., Paecilomyces spp., and
Trichophyton rubrum [58••]. MAb476 therefore differed from
the EBA2 antibody used in Platelia®GMEIA, which showed
also affinity to A. terreus and Histoplasma capsulatum C Ag
[58••]. While these two antibodies may show affinity to dif-
ferent epitopes of the GM-like Ag, which would explain the
differences, the detailed structure of the GM-like Ag has not
yet been revealed [58••].
As a next step, Dufresne and colleagues successfully
constructed a MAb476-based LFD prototype for urine
POC testing. The functionality of MAb476 testing was
confirmed with human urine samples, which were obtain-
ed from healthy volunteers and spiked with in vitro-pro-
duced Aspergillus antigen [58••]. However, when retro-
spectively testing stored samples which were collected
from 11 patients who were categorized as probable/
proven IA and showed positive serum GM results, sensi-
tivity was imperfect, as only samples from 4 out of these
11 patients also had positive test results with the
MAb476-sELISA and MAb476-LFD after pretreatment
[58••]. Importantly, MAb476 testing appeared to be
inhibited by an unknown substance or mix of substances
in human urine, and this effect positively correlated to the
specific mass of the urine samples [58••]. Boiling and
centrifugation were not able to abandon the inhibition,
and the relevant substances appeared to weigh less than
2 kDa [58••]. Urine sample concentration (5–10 fold),
Table 3 Sensitivity of BALF LFD for probable/proven IPA in patients
with and without antifungal prophylaxis/therapy (information only
available for a proportion of cases published).a
BALF LFD sensitivity
for IPA overall percentage
(absolute numbers)
Overall 75% (50/67)
Under mold active systemic antifungals 56% (14/25)
Without mold active antifungals 86% (36/42)
BALF bronchoalveolar lavage fluid, IPA invasive pulmonary aspergillo-
sis, LFD lateral flow device
a Data derived from [8•], updated with [16••, 45, 46]
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followed by desalting/dialysis (7 kDa), resulted in a near-
ly complete diminution of the inhibition [58••].
While these results on development of the MAb476-LFD
for urine samples were promising, it has to be kept in mind
that the sample size was limited and the study settings were
non-clinical and animal models in large parts. Additionally,
the quality of the clinical samples and other information about
the patients (like the presence of antifungal treatment) could
not be satisfactorily evaluated [58••]. Referring to the planned
use in clinical settings, the MAb476-LFD needs further opti-
mization to fit requirements for a reliable POC device, which
is currently ongoing.
Conclusion
Important advances have been made in the development of
lateral flow assays for invasive aspergillosis. Most promising
is the Aspergillus-specific lateral-flow device test, which is
based on the JF5 antibody and has shown convincing perfor-
mance in multiple clinical studies, in particular in BALF sam-
ples. Commercial availability is still pending, however.
Recently, an LFD prototype for urine POC testing based on
MAB476 has been constructed, which is currently undergoing
further evaluation in studies with bigger sample sizes. Overall,
the evaluation of the diagnostic performance of new assays in
IA remains problematic, as the vast majority of IA cases are
“probable” cases and there is no established diagnostic test in
clinical routine that provides sensitivity high enough to qual-
ify the test as a reliable gold standard.
The search for reliable antigen-based POC tests for other
molds, including mucorales, continues [63]. Recently, an
enzyme-linked immunospot assay has been developed, for
detection of Mucorales-specific T cells in peripheral blood
samples [63]. Mucorales-specific T cells polarized to the pro-
duction of T helper type 2 cytokines were associated with
proven invasive mucormycosis and may be detected by
immunoenzymatic assays or immunocytofluorimetric assays
[63]. Once validated, that assay may represent a breakthrough
in diagnosis of invasive mucormycosis [63].
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